Cardinal Health (NYSE:CAH)’s value rating was downgraded by StockNews.com

Cardinal Health (NYSE:CAH – Get Rating) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday.

Several other research firms also recently issued reports on CAH. Mizuho lifted their price objective on Cardinal Health from $66.00 to $74.00 and gave the stock a “neutral” rating in a report on Monday, November 14th. Credit Suisse Group lifted their price objective on Cardinal Health from $64.00 to $79.00 and gave the stock a “neutral” rating in a report on Tuesday, November 22nd. Morgan Stanley upped their price objective on Cardinal Health from $76.00 to $82.00 and gave the stock an “overweight” rating in a report on Monday, November 7th. UBS Group boosted their target price on Cardinal Health from $61.00 to $78.00 and gave the company a “buy” rating in a report on Monday, August 29th. Finally, Bank Of America (Bofa) raised Cardinal Health from an “underperform” rating to a “neutral” rating and upped their target price for the company from $64.00 to $80.00 in a report on Friday, November 4th. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $76.45, based on data from MarketBeat.

Cardinal performance of health stocks

Shares of NYSE:CAH traded up $0.06 during mid-day trading on Monday, reaching $79.34. 2,427,959 shares of the company traded hands, compared to its average volume of 2,896,509. The firm has a market cap of $20.80 billion, a P/E ratio of 12.96, a PEG ratio of 1.32 and a beta of 0.81. Cardinal Health has a 52-week low of $48.41 and a 52-week high of $81.57. The firm’s 50-day simple moving average is $76.38, and its 200-day simple moving average is $66.66.

Cardinal Health (NYSE:CAH – Get Rating ) last announced its earnings results on Friday, November 4th. The company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.96 by $0.24. Cardinal Health had a negative return on equity of 252.82% and a negative net income of 0.59%. The business had revenue of $49.60 billion for the quarter, compared to the consensus estimate of $46.88 billion. equities analysts anticipate that Cardinal Health will post 5.27 EPS for the current fiscal year.

Inside Cardinal Health

In related news, insider Ola M. Snow sold 19,590 shares of the business’s stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $78.87, for a total transaction of $1,545,063.30. Following the completion of the transaction, the insider now owns 31,187 shares in the company, valued at approximately $2,459,718.69. The transaction was disclosed in a legal filing with the Securities and Exchange Commission, which is available on the SEC’s website. Insiders own 0.17% of the company’s stock.

Institutional inflows and outflows

Institutional investors have recently added to or reduced their stakes in the business. BOK Financial Private Wealth Inc. acquired a new position in Cardinal Health in the 3rd quarter valued at $28,000. LS Investment Advisors LLC acquired a new stake in shares of Cardinal Health in the 2nd quarter valued at $27,000. Capital Advisors Ltd. LLC boosted its holdings in shares of Cardinal Health by 29.5% in the third quarter. Capital Advisors Ltd. LLC now owns 589 shares of the company’s stock valued at $39,000 after buying an additional 134 shares during the period. CX Institutional acquired a new stake in shares of Cardinal Health in the second quarter valued at $33,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Cardinal Health by 422.0% in the third quarter. EverSource Wealth Advisors LLC now owns 642 shares of the company’s stock valued at $43,000 after buying an additional 519 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s shares.

Cardinal Health Company Profile

(Get Rating)

Cardinal Health, Inc operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia and internationally. Provides customized solutions for hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients at home.

More information

Analyst Recommendations for Cardinal Health (NYSE:CAH)

This instant news alert is generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider Cardinal Health, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients daily. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market takes a nosedive … and Cardinal Health wasn’t on the list.

While Cardinal Health currently has a “Hold” rating among analysts, the top-rated analysts think these five stocks are better buys.

Check out the five stocks here

20 shares for sale now

MarketBeat just published its list of 20 stocks that Wall Street analysts hatred. These companies may look like they have good fundamentals, but top analysts smell something seriously rotten. Are there any of these companies lurking around your portfolio? Find out by entering your email address below.

Get this free report

20 stocks for sale now Cover

Leave a Comment

Your email address will not be published. Required fields are marked *